Inicio>>Signaling Pathways>> Others>>FB23-2

FB23-2

Catalog No.GC36032

FB23-2 es un inhibidor potente y selectivo de la desmetilasa FTO de ARNm N6-metiladenosina (m6A), con una IC50 de 2,6 μM. FB23-2 tiene actividad antiproliferaciÓn. FB23-2 se puede utilizar para la investigaciÓn de la leucemia mieloide aguda (LMA).

Products are for research use only. Not for human use. We do not sell to patients.

FB23-2 Chemical Structure

Cas No.: 2243736-45-8

Tamaño Precio Disponibilidad Cantidad
10mM (in 1mL DMSO)
92,00 $
Disponible
1mg
30,00 $
Disponible
5mg
84,00 $
Disponible
10mg
143,00 $
Disponible
50mg
525,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

FB23-2 is a potent and selective inhibitor of mRNA N6-methyladenosine (m6A) demethylase FTO, with an IC50 of 2.6 μM[1]. IC50: 2.6 μM (FTO)[1]

FB23-2 dramatically suppresses proliferation and promotes the differentiation/apoptosis of human acute myeloid leukemia (AML) cell line cells and primary blast AML cells[1]. FB23 inhibits the proliferation of NB4 and MONOMAC6 cells, with IC50 values of 0.8 μM and 1.5 μM[1].

FB23-2 significantly inhibits the progression of human AML cell lines and primary cells in xeno-transplanted mice[1].

[1]. Huang Y, et al. Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia. Cancer Cell. 2019 Apr 15;35(4):677-691.e10.

Reseñas

Review for FB23-2

Average Rating: 5 ★★★★★ (Based on Reviews and 20 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for FB23-2

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.